Drug resistance mutations of HIV Type 1 Non-B viruses to integrase inhibitors in treatment-naive patients from sub-saharan countries and discordant interpretations

AIDS Research and Human Retroviruses

Volumn 28, Issue 9, 2012, Pages 957-960

  Monleau, Marjorie ^a   Aghokeng, Avelin F ^a,b   Nkano, Benedicte A ^b   Chaix, Marie Laure ^c   Peeters, Martine ^a  

^a UNIVERSITÉ DE MONTPELLIER   (France)

^b Institut de Recherche pour le Developpement Cameroon   (Cameroon)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE; INTEGRASE INHIBITOR; RALTEGRAVIR;

ALGORITHM; ARTICLE; DRUG EFFICACY; DRUG RESPONSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; VIRUS MUTATION;

EID: 84865466725     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0326     Document Type: Article

References (12)

1. Kobayashi M, Yoshinaga T, Seki T, et al.: In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011; 55 (2):813-821.
2. Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, Marcelin AG, and Perno CF: Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev 2009; 11 (1):17-29.
3. Marcelin AG, Ceccherini-Silberstein F, Perno CF, and Calvez V: Resistance to novel drug classes. Curr Opin HIV AIDS 2009;4 (6):531-537.
4. Blanco JL, Varghese V, Rhee SY, Gatell JM, and Shafer RW: HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 2011;203 (9):1204-1214.
5. Vidal N, Mulanga C, Bazepeo SE, et al.: HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in the Democratic Republic of Congo (DRC). AIDS Res Hum Retroviruses 2006;22 (2):202-206. (Pubitemid 43277157)
6. Garrido C, Geretti AM, Zahonero N, et al.: Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. J Antimicrob Chemother 2010; 65 (2):320-326.
7. Rhee SY, Liu TF, Kiuchi M, et al.: Natural variation of HIV-1 group M integrase: Implications for a new class of antiretroviral inhibitors. Retrovirology 2008;5:74.
8. Varghese V, Liu TF, Rhee SY, et al.: HIV-1 integrase sequence variability in antiretroviral naive patients and in triple-class experienced patients subsequently treated with raltegravir. AIDS Res Hum Retroviruses 2010;26 (12):1323-1326.
9. Malet I, Delelis O, Valantin MA, et al.: Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 2008;52 (4):1351-1358. (Pubitemid 351521998)
10. Ghosn J, Mazet AA, Avettand-Fenoel V, et al.: Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravircontaining regimen. J Antimicrob Chemother 2009;64 (2): 433-434.
11. Fish MQ, Hewer R, Wallis CL, Venter WD, Stevens WS, and Papathanasopoulos MA: Natural polymorphisms of integrase among HIV type 1-infected South African patients. AIDS Res Hum Retroviruses 2010;26 (4):489-493.
12. Vergne L, Snoeck J, Aghokeng A, et al.: Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients. FEMS Immunol Med Microbiol 2006;46 (1):53-62.